Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS2770569 A
Publication typeGrant
Publication dateNov 13, 1956
Filing dateOct 15, 1952
Priority dateAug 1, 1952
Publication numberUS 2770569 A, US 2770569A, US-A-2770569, US2770569 A, US2770569A
InventorsGruessner Andre, Pellmont Bela, Fromherz Konrad, Schnider Otto
Original AssigneeHoffmann La Roche
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Analgesic compositions
US 2770569 A
Abstract  available in
Images(2)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

Patented Nov. 135,

ANALGESHI (IOMPOSITIONS Konrad Fromlierz, Andre Grnessner, Bela Pellmont, and

Otto Schnider, Basel, Switzerland, assignors to Hoffmann-La Roche Inc, Nutley, N. 3., a corporation of New Jersey No Drawing. Application Uctobcr 15, 1952, Serial No. 314,954

Claims priority, application Switzerland August 1, 1952 6 Claims. (Cl. 167--65) This invention relates to compositions of matter useful in therapy to produce analgesia. It relates especially to such compositions wherein undesired side effects common to analgesics, particularly respiratory depression, are diminished or suppressed by incorporation of material which antagonizes the tendency of the analgesic material to produce such side effects.

Morphine-type analgesics have found extensive medical application because of their fi"1cacy even in cases of very severe pain. However, overdoses of such analgesics often are attended by very serious side reactions. In addition, many people react even to minimal therapeutic doses by exhibiting similar side reactions, which are mainly evidenced in the form of respiratory depression, nausea, and vomiting. In the management of labor, analgesic medication administered to the mother often results in respiratory depression of the newborn infant.

The present invention rests upon the discovery that levo-3-hydroxy-N-allyl-rnorphinan, either in the form of the free base or in the form of its acid addition salts, has the characteristic of suppressing or eliminating undesired side reactions of morphine-type analgesics. Surprisingly, it has been found that this antagonistic effect of 3-hydroxy-N-allyl-morphinan is limited to the levo enantiomorph thereof; the dextro form having little or no antagonistic effect; and the racemic form having the activity only of its levo content.

The antagonistic effect of levo-3-hydroxy-N-allylmorphinan extends not only to the undesired side reactions of morphine-type analgesics but also extends to the analgesic activity itself. Accordingly, the dosage of the antagonist, levo-3-hydroxy-N-allylmorphinan, must be carefully proportioned with respect to the dosage of the analgesic material so as to diminish or suppress the side reactions without significantly influencing the desired analgesic action. Fortunately, the effect of a small proportion of levo-3-hydroxy-N-allyl-morphinan upon the side reactions, particularly the respiratory depressive effect, is considerable; whereas the antagonistic effect on the analgesic action, produced by that same small proportion of levo-3-hydroxy-N-allyl-morphinan, is small. It has been found that good results have been obtained when the proportion of levo-3-hydroxy-N-allyl-morphinan is from about to about by weight of the morphinetype analgesic material. It will be appreciated by those skilled in the art, however, that these numerical values are not absolutely limiting; and compositions wherein the proportion of analgesic material and antagonist material differs slightly from the range indicated above, but which exhibit the desirable qualities indicated in this disclosure, are equivalent to the compositions described in detail herein and are comprehended within the scope of the invention disclosed in this specification.

Accordingly, the present invention provides compositions of matter containing as essential therapeutic ingredients morphine-type analgesic material and antagonist maicrial selected from the group consisting of levo-3-hydroxy-N-allyl-morphinan and its acid addition salts, the effective content of levo-3-hydroxy-N-allyl-morphinan in said compositions being from about 0.5 percent to about 10 percent by weight of said analgesic material.

Morphine-type analgesics includes morphine itself and analgesically active derivatives and synthetic substitutes therefor, as discussed in parts II and III of a paper by Bergel and Morrison in Quarterly Reviews of the Chemical Society, vol. II, pages 349-382 (194-8), and in a paper by Eddy in Journal of the American Pharmaceutical Association (Scientific Edition) vol. 39, pages 245251 (1950). Illustrative morphine-type analgesics include morphine and its derivatives, 3-hydroxy-N-methyl-morphinan, 1-methyl-4-phenyl-piperidine-4carboxylic acid ethyl ester, 1,3-dimethyl-4-phenyl-4-propionoxypiperidine, 1-methyl-4- (m-hydroxyphenyl) -piperidine-4- ethyl ketone, 4,4-diphenyl-6-dimethylamino-heptan-3-one and acid addition salts thereof. It will be understood by those skilled in the art that these analgesic materials can be used either as the free bases or in the form of their acid addition salts, and can be used individually or in combination with each other when desirable. Moreover, since these compounds typically exhibit optical isomerism, it will be understood that any of the optically active or racemic forms possessing significant analgesic activity can be used in practicing the invention. Mixtures of free bases and salts, or of racemic and optically active forms, or of analgesics having different chemical constitutional formuias, or any combination of tl foregoing materials, can be employed.

Similarly, since racemic 3-hydroxy-Nallyl-1norphinan exhibits the antagonistic effect discussed. above, in consequence of its content of the levo enantiomorph, it should be understood that the levo content of the compositions of the invention may be present in whole or in part as a constituent of racemic 3-hydroxy-N-allyl-rnorphinan. Likewise, the antagonist may be used either in the form of the free base 3-hydroxy-N-allyl-morphinan, or in the form of an acid addition salt of 3-hydroxy-N allyl-mon phinan, or as a mixture of the base and acid addition salts thereof, either levo or racemic.

The total content of antagonist material present in compositions of matter according to the invention should provide from about 0.5 percent by weight to about 10 percent by Weight of the free base levo-3-hydroxy-N allyl'morphinan, based upon the total weight of analgesic material in the composition. In addition to their analgesic content and antagonist content, it will be obvious to those skilled in the art that compositions of matter according to the invention may also be formulated to contain pharmaceutical adjuvant material of various sorts, e. g. carriers, buffers, antiseptics, flavoring agents, stabilizers, diluents and the like.

A preferred aspect of the invention relates to compositions of matter containing as essential therapeutic ingredients: analgesic material selected from the group consisting of morphine, dihydrodesoxymorphine, 3-hydroxy- N--methyl-morphinan, 1-methyl-4-phenyl-piperidine-4-carboxylic acid ethyl ester, l,3-dimethyl-4-phenyl-4-propionoxy-riperidine, 1-methyl-4-(m-hydroxyphenyl -piperidinetethyl ketone, 4,4-diphenyl-6-dimethylaminoheptan-3- one and acid addition salts thereof; and antagonist maerial selected from the group consisting of levo-3-hydroxyl-sllyl-morphinan and its acid addition salts; the effective cor out of levo-3-hydroxy-N-ally1-morphinan in said composit. .n being from about 0.5 percent to about 19 percent by weight of said analgesic material.

A particularly preferred embodiment of the invention relates to compositions of matter in dosage unit form consisting essentially of an acid addition salt of levo-3- hydroxy-Nanethyl-morphinan, an acid addition salt of 3 lave-3-hydroxy-N-allyl-morphinan, and pharmaceutical adjuvant material, the proportion of said levo-3-hydroxy- N-allyl-morphinan to said levo-3-hydroxy-N-methylmorphinan being from about 0.5 percent to about 10 percent by weight.

A second particularly preferred embodiment of the in vention relates to compositions of matter in dosage unit form consisting essentially of an acid addition salt of racemic-3-hydroxy-N-methyl-morphinan, an acid addition salt of levo-3-hydroxy-N-allyl-rnorphinan, and pharmaceutical adjuvant material, the proportion of said levo-3-hydroxy-N-allyhmorphinan to said racemic-3-hydroxy-N- methyl-morphinan being from about 0.5 percent to about 10 percent by weight.

The invention is further disclosed in the following examples, which are illustrative but not limitative thereof.

Example 1 To a paste prepared from 54 g. of cornstarch, were added 1.5 g. of levo-3-hydroxy-N-methyl-morphinan tartrate, 0.1 g. of levo-3-hydroxy-N-allyl-morphinan tartrate, 90 g. of milk sugar, 4.2 g. of talc, and 0.2 g. stearin. The ingredients were mixed homogeneously, the whole granulated through a sieve, dried, and made up into tablets, each weighing 150 mg. and each containing 1.5 mg. of levo-3-hydroxy-N-methyl-morphinan tartrate and 0.1 mg. levo-3-hydroxy-N-allyl-morphinan tartrate.

Another type of tablets was made, exactly similar to those described above, except that the 1.5 mg. of levo- 3-hydroxy-N-methyl-morphinan tartrate was replaced by 3.0 mg. of racemic-3-hydroxy-N-methyl-morphinan tartrate.

Tablets similar to those described above were made by substituting 20 mg. of morphine hydrochloride for the 1.5 mg. of levo-3-hydroxy-N-methyl-morphinan tartrate.

Tablets similar to those described above were also made by substituting mg. of 1-methyl-4-(m-hydroxyphenyl)- piperidine-4-ethyl-ketone hydrochloride for the 1.5 mg. of levo-3hydroxy-N-methyl-morphinan tartrate.

Example 2 3 g. of dihydrodesoxymorphine hydrobromide, and 0.1 g. of levo-3-hydroxy-IJ-allyl-rnorphinan hydrobromide were dissolved in a mixture of cc. of water and 30 cc. of ethanol, and mixed with 2000 g. of cocoa butter and 100 g. of white wax to form a homogeneous mass. From the latter were prepared suppositories each containing 3 mg. of dihydrodesoxymorphine hydrobromide and 0.1 mg. of levo-3-hydroXy-N-allyl-morphinan hydrobromide.

Example 3 A solution was prepared from double distilled water containing in each cc. 4 mg. of dihydrodesoxymorphine hydrobromide, and 0.1 mg. of levo-3-hydroxy-N-allylmorphinan hydrobromide. The solution was filled into ampuls and heated for minutes at 95 C. in order to sterilize the same.

Example 4 In 900 cc. of double distilled water were dissolved 0.8 g. of p-hydroxy-benzoic acid methyl ester 0.1 g. of p-hydroxy-benzoic acid propyl ester 3.0 g. of levo-3-hydroxy-N-methyl-morphinan tartrate 0.15 g. of levo-3-hydroxy-N-allyl-morphinan tartrate.

The solution was set to pH 6.0 by adding approximately 7.4 cc. of normal NaOH, adjusted to 1000 cc. with double distilled water and filled into 1 cc. ampuls.

Example5 9 g. of levo-3-hydroxy-N-methyl-morphinan tartrate,

and 0.45 g. of lev0-3 hydroxy-N-allyl-morphinan tartrate were dissolved in 165 cc. of ethanol, 2.4 g. of p-hydroxy benzoic acid methyl ester and 0.3 g. of p-hydroxy benzoic acid propyl ester were added, the clear solution was set to 3000 cc. with double distilled water, and filtered. This solution can be prescribed for administration as a drops solution. Twenty drops, corresponding to about 1 cc., contain 3 mg. of levo-3-hydroxy-N-methyl-morphinan tartrate and 0.15 mg. of 3-hydroxy-N-allyl-morphinan tartrate.

We claim:

1. A composition of matter in a form for administration by injection containing as essential therapeutic ingredients: analgesic material selected from the class consisting of morphine, dihydrodesoxymorphine, 3-hydroxy-N-methylmorphinan, 1-methyl-4-phenyl-piperidine-4-carboxylic acid ethyl ester, l,3dimethyl-4-phenyl-4-propionoxy-piperidine, l-methyl-4-(m-hydroxyphenyl) piperidine4-ethyl ketone, 4,4-diphenyl-6-dimethylamino-heptan-3-one and acid addition salts thereof; and antagonist material selected from the group consisting of levo-3-hydroxy-N-allylmorphinan and its acid addition salts; the effective content of levo-3-hydroxy-N-allyl-morphinan in said composition being from about 0.5 percent to about 10 percent by Weight of said analgesic material.

2. A composition of matter in dosage unit form for administration by in ection consisting essentially of an acid addition salt of 1evo-3-hydroxy-N-methyl-morphinan, an acid addition salt of levo-3-hydroxy-N-allyl-morphinan, and pharmaceutical adjuvant material, the proportion of said levo3-hydroxy-N-allyl-morphinan to said levo-3-hydroxy-N-methyl-morphinan being from about 0.5 percent to about 10 percent by weight.

3. A composition of matter in dosage unit form for administration by injection consisting essentially of an acid addition salt of racemic-3-hydroxy-N-methyl-morphinan, an acid addition salt of levo-3-hydroxy-N-allyl-morphinan, and pharmaceutical adjuvant material, the proportion of said levo-3-hydroxy-N-allyl-morphinan to said racemic-3 hydroxy-N-methyl-morphinan being from about 0.5 percent to about 10 percent by weight.

4. A composition of matter in a form for administration by injection containing as essential therapeutic ingredients morphine-type analgesic material and antagonist material selected from the group consisting of levo-3-hydroxy-N-allyl-rnorphinan and its acid addition salts, the effective content of levo-3-hydroxy-N-allyl-morphinan in said composition being from about 0.5 percent to about 10 percent by weight of said analgesic material.

5. A composition according to claim 4 wherein said morphine-type analgesic material comprises a substantial 1 proportion of levo-3-hydroxy-N-methyl-morphinan.

6. A composition according to claim 4 wherein said morphine-type analgesic material comprises a substantial proportion of an acid addition salt of levo-3-hydroxy-N- methyl-morphinan.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2683106 *Jul 28, 1949Jul 6, 1954Lewenstein Mozes JudaAnalgesic composition
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3285922 *Oct 25, 1963Nov 15, 1966Research CorpN-cyclopropylmethyl-and -cyclobutyl-methyl-morphinans
US3301855 *Mar 2, 1964Jan 31, 1967Ciba Geigy CorpDerivatives of 4-nu-(2-nu, nu-dimethylaminolower alkyl)-amino quinazoline
US3320262 *Sep 22, 1964May 16, 1967Lewenstein14 hydroxy morphine and codeine carboxymethyloximes
US3493657 *Jan 23, 1964Feb 3, 1970Mozes Juda LewensteinTherapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3966940 *Sep 2, 1975Jun 29, 1976Bristol-Myers CompanyAnalgetic compositions
US5321012 *Apr 6, 1993Jun 14, 1994Virginia Commonwealth University Medical CollegeInhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US6228863Dec 22, 1998May 8, 2001Euro-Celtique S.A.Method of preventing abuse of opioid dosage forms
US6277384Dec 22, 1998Aug 21, 2001Euro-Celtique S.A.Opioid agonist/antagonist combinations
US6375957Feb 11, 2000Apr 23, 2002Euro-Celtique, S.A.Opioid agonist/opioid antagonist/acetaminophen combinations
US6475494Mar 22, 2001Nov 5, 2002Euro-Celtique S.A.Opioid agonist/antagonist combinations
US6627635Mar 22, 2001Sep 30, 2003Euro-Celtique S.A.Method of preventing abuse of opioid dosage forms
US6696066Sep 16, 2002Feb 24, 2004Euro-Celtique S.A.Opioid agonist/antagonist combinations
US6696088Feb 8, 2001Feb 24, 2004Euro-Celtique, S.A.Tamper-resistant oral opioid agonist formulations
US6716449Feb 8, 2001Apr 6, 2004Euro-Celtique S.A.Controlled-release compositions containing opioid agonist and antagonist
US7172767Oct 27, 2003Feb 6, 2007Purdue Pharma L.P.Opioid agonist / antagonist combinations
US7384653Sep 23, 2004Jun 10, 2008Purdue Pharma L.P.Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7419686Dec 26, 2006Sep 2, 2008Purdue Pharma L.P.Opioid agonist/antagonist combinations
US7658939Nov 4, 2003Feb 9, 2010Purdue Pharma L.P.Tamper-resistant oral opioid agonist formulations
US7682632Mar 23, 2010Purdue Pharma L.P.Tamper-resistant oral opioid agonist formulations
US7682633Mar 6, 2009Mar 23, 2010Alpharma Pharmaceuticals, LlcPharmaceutical composition
US7682634Mar 6, 2009Mar 23, 2010Alpharma Pharmaceuticals, LlcPharmaceutical compositions
US7718192Nov 4, 2003May 18, 2010Purdue Pharma L.P.Tamper-resistant oral opioid agonist formulations
US7749542Jul 28, 2008Jul 6, 2010Purdue Pharma LpOpioid agonist/antagonist combinations
US7842309Nov 30, 2010Purdue Pharma L.P.Tamper-resistant oral opioid agonist formulations
US7842311Nov 30, 2010Purdue Pharma L.P.Tamper-resistant oral opioid agonist formulations
US7914818Aug 6, 2002Mar 29, 2011Purdue Pharma L.P.Opioid agonist formulations with releasable and sequestered antagonist
US7943173Jul 18, 2002May 17, 2011Purdue Pharma L.P.Pharmaceutical combinations of oxycodone and naloxone
US8105631May 24, 2010Jan 31, 2012Purdue Pharma L.P.Opioid agonist/antagonist combinations
US8158156Jun 19, 2007Apr 17, 2012Alpharma Pharmaceuticals, LlcAbuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8182836Jun 5, 2009May 22, 2012Elite Laboratories, Inc.Abuse-resistant oral dosage forms and method of use thereof
US8231901Mar 8, 2011Jul 31, 2012Purdue Pharma L.P.Opioid agonist formulations with releasable and sequestered antagonist
US8236351Oct 21, 2010Aug 7, 2012Purdue Pharma L.P.Tamper-resistant oral opioid agonist formulations
US8357399Jan 22, 2013Purdue Pharma L.P.Tamper-resistant oral opioid agonist formulations
US8425933Dec 17, 2009Apr 23, 2013Elite Laboratories, Inc.Abuse-resistant oral dosage forms and method of use thereof
US8465774Feb 13, 2006Jun 18, 2013Purdue Pharma L.P.Sequestered antagonist formulations
US8518443Jun 28, 2012Aug 27, 2013Purdue Pharma, L.P.Opioid agonist formulations with releasable and sequestered antagonist
US8518925Jun 8, 2005Aug 27, 2013Euro-Celtique S.A.Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
US8586088Dec 18, 2012Nov 19, 2013Purdue Pharma L.P.Tamper-resistant oral opioid agonist formulations
US8603528 *Jul 25, 2006Dec 10, 2013Abyrx, Inc.Compositions and method for the reduction of post-operative pain
US8623418Dec 16, 2008Jan 7, 2014Alpharma Pharmaceuticals LlcPharmaceutical composition
US8673355Dec 27, 2011Mar 18, 2014Purdue Pharma L.P.Opioid agonist/antagonist combinations
US8685443Apr 23, 2010Apr 1, 2014Alpharma Pharmaceuticals LlcSequestering subunit and related compositions and methods
US8685444Apr 23, 2010Apr 1, 2014Alpharma Pharmaceuticals LlcSequestering subunit and related compositions and methods
US8703186Apr 16, 2013Apr 22, 2014Elite Laboratories, Inc.Abuse-resistant oral dosage forms and method of use thereof
US8758825May 22, 2013Jun 24, 2014Purdue Pharma L.P.Sequestered antagonist formulations
US8815287Jul 29, 2013Aug 26, 2014Purdue Pharma L.P.Opiod agonist formulations with releasable and sequestered antagonist
US8822487Dec 7, 2012Sep 2, 2014Purdue Pharma L.P.Opioid agonist/opioid antagonist/acetaminophen combinations
US8846090Jan 11, 2012Sep 30, 2014Euro-Celtique S.A.Matrix for sustained, invariant and independent release of active compounds
US8846091Oct 18, 2013Sep 30, 2014Euro-Celtique S.A.Matrix for sustained, invariant and independent release of active compounds
US8846104Feb 13, 2012Sep 30, 2014Alpharma Pharmaceuticals LlcPharmaceutical compositions for the deterrence and/or prevention of abuse
US8877247Feb 22, 2010Nov 4, 2014Alpharma Pharmaceuticals LlcAbuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8932630Sep 18, 2014Jan 13, 2015Purdue Pharma L.POpioid agonist/antagonist combinations
US8936808Sep 18, 2014Jan 20, 2015Purdue Pharma L.P.Opioid agonist/opioid antagonist/acetaminophen combinations
US8936812Oct 4, 2013Jan 20, 2015Purdue Pharma L.P.Tamper-resistant oral opioid agonist formulations
US8969369Dec 20, 2013Mar 3, 2015Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9056051Mar 11, 2014Jun 16, 2015Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
US9084729Oct 30, 2013Jul 21, 2015Purdue Pharma L.P.Abuse-resistant controlled-release opioid dosage form
USRE39221Jan 20, 2004Aug 1, 2006Ortho-Mcneil Pharmaceutical, Inc.Composition comprising a tramadol material and acetaminophen and its use
USRE39300Jun 15, 2001Sep 19, 2006Virginia Commonwealth University Medical College Of VirginiaInhibiting the development of tolerance to and/or dependence on an addictive substance
Classifications
U.S. Classification514/282
International ClassificationA61K31/485
Cooperative ClassificationA61K31/485
European ClassificationA61K31/485